Phase I, pharmacokinetic, and pharmacodynamic study of intravenously administered Ad5CMV-p53, an adenoviral vector containing the wild-type p53 gene, in patients with advanced cancer.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Anthony W TolcherS Gail Eckhardt

Abstract

The purpose of this study was to assess the feasibility of administering Ad5CMV-p53, an adenoviral vector containing the wild-type p53 gene to patients with advanced malignancies, characterize the pertinent pharmacokinetic parameters, identify evidence of viral uptake in both normal and tumor tissue, and seek evidence of antitumor activity. Patients were treated with escalating doses of Ad5CMV-p53 intravenously over 30 minutes on days 1, 2, and 3, every 28 days. The clearance of circulating Ad5CMV-p53 (INGN 201) DNA was characterized in the plasma and paired tumor and skin biopsies were performed in patients treated at the two highest dose levels to assess vector uptake into tissues. Seventeen patients received 36 courses of Ad5CMV-p53 at doses ranging from 3 x 10(10) to 3 x 10(12) virus particles (vp). Fatigue, nausea, vomiting, and fever were common, but rarely severe. Abnormalities of coagulation parameters, including decreases in fibrinogen and increases in fibrin degradation products at 3 x 10(12)vp, precluded additional dose escalation. Ad5CMV-p53 DNA could be detected in the plasma by polymerase chain reaction assay in the majority of patients at 14 days and 28 days at doses of 3 x 10(10) and higher. Six patients treated...Continue Reading

References

Jul 5, 1991·Science·M HollsteinC C Harris
Jun 6, 1991·Nature·A J LevineC A Finlay
Oct 27, 1989·Science·T TakahashiJ D Minna
Jun 17, 1998·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·G L ClaymanH Goepfert
May 18, 1999·Journal of the National Cancer Institute·S G SwisherM K Waugh
Feb 2, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J NemunaitisJ Roth
Mar 15, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Steven HirschfeldRichard Pazdur
Jul 4, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Frederick F LangW K Alfred Yung

❮ Previous
Next ❯

Citations

Jan 14, 2010·Molecular Therapy : the Journal of the American Society of Gene Therapy·Daniel H StermanSteven M Albelda
Dec 14, 2007·Nature Reviews. Cancer·Dario C Altieri
Mar 19, 2008·Molecular Cancer Therapeutics·James F CurtinMaria G Castro
Sep 28, 2007·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·Ute FischerKlaus Schulze-Osthoff
Jun 7, 2013·Therapeutic Delivery·Stephany Y Tzeng, Jordan J Green
Sep 15, 2010·Expert Review of Anticancer Therapy·Sandra Schmitz, Jean-Pascal Machiels
Oct 20, 2006·Expert Opinion on Biological Therapy·Christopher Y WooMichael A Morse
Feb 27, 2009·Expert Opinion on Investigational Drugs·Patricia Moretto, Sébastien J Hotte
Jul 22, 2006·Expert Opinion on Biological Therapy·Dmitry I Gabrilovich
Jun 11, 2009·Drug Discovery Today·Pin-I HuangTa-Chiang Liu
May 7, 2008·Journal of Cellular Biochemistry·Jessica PlatiRoya Khosravi-Far
Oct 13, 2010·Alimentary Pharmacology & Therapeutics·Y TouchefeuG Vassaux
Apr 19, 2016·Molecular Therapy. Methods & Clinical Development·Guy UngerechtsDirk M Nettelbeck
Jul 6, 2013·Regulatory Toxicology and Pharmacology : RTP·Pei-jian YueYing Peng
Jan 17, 2015·Regulatory Toxicology and Pharmacology : RTP·Pei-jian YueYing Peng
May 26, 2017·Wiley Interdisciplinary Reviews. Nanomedicine and Nanobiotechnology·Rami Walid ChakrounHonggang Cui
Jan 18, 2018·Human Gene Therapy·Wei-Wei ZhangDominic Man-Kit Lam
Jan 12, 2007·Leukemia·W J ChngR Fonseca
Sep 21, 2007·The Journal of Gene Medicine·Ellen A M Schenk-BraatLeonie C M Kaptein

❮ Previous
Next ❯

Related Concepts

Related Feeds

CREs: Gene & Cell Therapy

Gene and cell therapy advances have shown promising outcomes for several diseases. The role of cis-regulatory elements (CREs) is crucial in the design of gene therapy vectors. Here is the latest research on CREs in gene and cell therapy.

Blood Clotting Disorders

Thrombophilia includes conditions with increased tendency for excessive blood clotting. Blood clotting occurs when the body has insufficient amounts of specialized proteins that make blood clot and stop bleeding. Here is the latest research on blood clotting disorders.